Drug intelligence / Profile preview

S-6204

Development stage: Preclinical
Lead developer: Seismic Therapeutics
Modality: Antibody-Based Therapeutics

Overview

S-6204 is an investigational IgE-targeted dissociator antibody being developed by Seismic Therapeutics for the treatment of allergic diseases. Discovered and optimized using Seismic's proprietary IMPACT machine learning platform, S-6204 is designed to rapidly dissociate IgE from its high-affinity receptor (FcεRI) on the surface of mast cells and basophils without triggering degranulation. Additionally, it prevents free IgE from binding to both FcεRI and the low-affinity IgE receptor (FcεRII/CD23), thereby neutralizing free IgE and down-modulating effector cell activation. S-6204 is currently in the undisclosed/exploratory stage of preclinical development.

Targets

IgE (Immunoglobulin E)FCER2 (Low affinity immunoglobulin epsilon fc receptor)FCGR2B (Fc gamma receptor IIB)FCER1 (Fc epsilon RI receptor)

Beyond the preview

Go deeper on S-6204.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S-6204.

Explore the full profile